Drug Profile
Research programme: antibody-based cancer therapeutics - Genexine/Nascent Biologics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Genexine; Nascent Biologics
- Developer Genexine; Nascent Biotech
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Brain-cancer in South Korea (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Brain-cancer in USA (Parenteral)
- 29 Jul 2014 Nascent Biologics has merged with Jin-En International Group Holding to form Nascent Biotech